| Phase separation mediates NUP98 fusion oncoprotein leukemic transformation B Chandra, NL Michmerhuizen, HK Shirnekhi, S Tripathi, BJ Pioso, ... Cancer discovery 12 (4), 1152-1169, 2022 | 82 | 2022 |
| Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma AC Birkeland, SK Foltin, NL Michmerhuizen, RC Hoesli, AJ Rosko, S Byrd, ... Oral oncology 68, 5-8, 2017 | 79 | 2017 |
| Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies NL Michmerhuizen, JM Klco, CG Mullighan Blood, The Journal of the American Society of Hematology 136 (20), 2275-2289, 2020 | 71 | 2020 |
| Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma R Hoesli, AC Birkeland, AJ Rosko, M Issa, KL Chow, NL Michmerhuizen, ... Oral oncology 77, 83-89, 2018 | 67 | 2018 |
| Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine NL Michmerhuizen, AC Birkeland, CR Bradford, JC Brenner Genes & cancer 7 (5-6), 182, 2016 | 56 | 2016 |
| Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma AC Birkeland, M Yanik, BN Tillman, MV Scott, SK Foltin, JE Mann, ... JAMA Otolaryngology–Head & Neck Surgery 142 (6), 559-567, 2016 | 44 | 2016 |
| Poly (amidoamine) dendrimer–methotrexate conjugates: the mechanism of interaction with folate binding protein MA van Dongen, R Rattan, J Silpe, C Dougherty, NL Michmerhuizen, ... Molecular pharmaceutics 11 (11), 4049-4058, 2014 | 43 | 2014 |
| Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low‐risk, nontraditional patients MA Gingerich, JD Smith, NL Michmerhuizen, M Ludwig, S Devenport, ... Head & neck 40 (5), 943-954, 2018 | 37 | 2018 |
| The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines ML Ludwig, A Kulkarni, AC Birkeland, NL Michmerhuizen, SK Foltin, ... Oral oncology 87, 144-151, 2018 | 32 | 2018 |
| Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC NL Michmerhuizen, E Leonard, A Kulkarni, JC Brenner Otorhinolaryngology-head and neck surgery 1 (2), 44, 2016 | 30 | 2016 |
| Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC JE Mann, R Hoesli, NL Michmerhuizen, SN Devenport, ML Ludwig, ... Journal of Cancer 8 (3), 332, 2017 | 28 | 2017 |
| An isothermal titration and differential scanning calorimetry study of the G-quadruplex DNA–insulin interaction CM Timmer, NL Michmerhuizen, AB Witte, M Van Winkle, D Zhou, ... The Journal of Physical Chemistry B 118 (7), 1784-1790, 2014 | 23 | 2014 |
| Rationale for using irreversible epidermal growth factor receptor inhibitors in combination with phosphatidylinositol 3-kinase inhibitors for advanced head and neck squamous … NL Michmerhuizen, E Leonard, C Matovina, M Harris, G Herbst, ... Molecular pharmacology 95 (5), 528-536, 2019 | 20 | 2019 |
| Genomic sequencing and precision medicine in head and neck cancers RC Hoesli, ML Ludwig, NL Michmerhuizen, AJ Rosko, ME Spector, ... European Journal of Surgical Oncology (EJSO) 43 (5), 884-892, 2017 | 16 | 2017 |
| Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy NL Michmerhuizen, JH Owen, ME Heft Neal, JE Mann, E Leonard, ... Journal of Neuro-oncology 147, 25-35, 2020 | 11 | 2020 |
| Head and neck cancer immunotherapy beyond the checkpoint blockade BR Heath, NL Michmerhuizen, CR Donnelly, K Sansanaphongpricha, ... Journal of Dental Research 98 (10), 1073-1080, 2019 | 10 | 2019 |
| Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma NL Michmerhuizen, ML Ludwig, AC Birkeland, S Nimmagadda, J Zhai, ... Head & neck 44 (5), 1192-1205, 2022 | 5 | 2022 |
| Phase separation mediates NUP98 fusion oncoprotein leukemic transformation. Cancer Discov. 2022; 12: 1152–1169. doi: 10.1158/2159-8290 B Chandra, NL Michmerhuizen, HK Shirnekhi, S Tripathi, BJ Pioso, ... CD-21-0674.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 5 | |
| Advancement of PI3 kinase inhibitor combination therapies for PI3K-aberrant chordoma MEH Neal, NL Michmerhuizen, KJ Kovatch, JHJ Owen, J Zhai, H Jiang, ... Journal of Neurological Surgery Part B: Skull Base 83 (01), 087-098, 2022 | 2 | 2022 |
| Rationale for using irreversible EGFR Inhibitors in combination with PI3K inhibitors for advanced Head and Neck Squamous Cell Carcinoma NL Michmerhuizen, E Leonard, C Matovina, M Harris, G Herbst, ... Molecular Pharmacology, 2019 | 2 | 2019 |
